Deal struck to supply 10 million Covid-19 testing kits

Medical diagnostic tests manufacturer, Abingdon Health, has signed a supply agreement with Taiwanese Arise Corporation for 10 million of its Abingdon Simply Test COVID-19 kits.

Arise was established in 1971 and is incorporated in Taiwan. It also has business activities in Japan, Singapore and other Asian countries.

Following execution of this agreement, York-based Abingdon will receive a purchase order for 10 million tests. The order will be subject to the Abingdon Simply Test receiving Taiwan Emergency Use Authorisation (EUA).

The EUA process is underway but Abingdon Health says it does not yet know the completion date of the EUA application review process.

The COVID-19 test is being provided by Abingdon Health in collaboration with a manufacturing partner.

As part of the supply agreement Arise Biotech also has an option to purchase a further 20 million Abingdon Simply Tests. Due to commercial confidentiality the purchase price of the tests is not being disclosed.

Chris Yates, CEO of Abingdon, said: “We must be clear with investors that fulfilment of this order depends on the successful completion of the Taiwan EUA application process, and we will update investors as soon as we can on this.”

Samuel Chou, chairman of Arise Corporation, commented: “We are greatly blessed with the opportunity to work with Abingdon Health, on our mission for global equitable access to diagnostics. May this project be yet another testimony of God’s grace.”